Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Valves01:16

Heart Valves

The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Impact of Myocardium at Risk in Transcatheter Aortic Valve Implantation.

Circulation. Cardiovascular interventions·2026
Same author

Three-Year Outcomes With a Supra-Annular, Self-Expanding Bioprosthesis and a Pericardial Wrap-The FORWARD PRO Study.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2024
Same author

Transcatheter Aortic Valve Replacement in Patients at High Risk of Coronary Obstruction.

Journal of the Society for Cardiovascular Angiography & Interventions·2024
Same author

Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study.

JACC. Cardiovascular interventions·2024
Same author

Cerebral embolic protection during transcatheter heart interventions.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2023
Same author

Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2023

Related Experiment Video

Updated: May 18, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Medtronic CoreValve Evolut valve.

Jan-Malte Sinning1, Nikos Werner, Georg Nickenig

  • 1Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Bonn, Germany.

Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
|September 22, 2012
PubMed
Summary

The 23 mm CoreValve Evolut bioprosthesis, a new generation device, expands treatment options for aortic stenosis patients. This report details the first implantation of this advanced, self-expanding valve in a 93-year-old female.

Related Experiment Videos

Last Updated: May 18, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Area of Science:

  • Cardiology
  • Medical Devices
  • Interventional Cardiology

Background:

  • The CoreValve Evolut is a next-generation, self-expanding bioprosthesis for aortic stenosis.
  • It offers technical refinements and is designed for potential future re-capturability.

Observation:

  • The first implantation of the 23 mm CoreValve Evolut was performed on June 1st, 2012.
  • The procedure took place at University Hospital Bonn, Germany.

Findings:

  • The 23 mm CoreValve Evolut is indicated for an aortic annulus range of 18 mm to 20 mm.
  • This device expands the patient population eligible for CoreValve bioprosthesis treatment.

Implications:

  • This advancement in transcatheter aortic valve replacement (TAVR) technology broadens treatment accessibility.
  • The CoreValve Evolut represents a significant step in managing severe aortic stenosis.